Award recognizes scientific innovation of first approved drug for underlying cause of nonsense mutation Duchenne muscular dystrophy
The award in the Medicines “Rare Disease” category recognizes the scientific innovation represented by Translarna’s ability to target the underlying cause of nonsense mutation Duchenne muscular dystrophy (nmDMD) and the impact the drug is having on nmDMD patients and their families.
Please click here for a full reading http://ir.ptcbio.com/releasedetail.cfm?ReleaseID=1003370
